Aquestive Therapeutics, Inc. Payment for Debt Extinguishment or Debt Prepayment Cost
Aquestive Therapeutics, Inc. (AQST) reported Payment for Debt Extinguishment or Debt Prepayment Cost of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-05.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtExtinguishmentCosts · last filed 2025-03-05
- Aquestive Therapeutics, Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Aquestive Therapeutics, Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2024-09-30 was $0.00.
- Aquestive Therapeutics, Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2024-06-30 was $0.00.
- Aquestive Therapeutics, Inc. payment for debt extinguishment or debt prepayment cost for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Aquestive Therapeutics, Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Aquestive Therapeutics, Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2023 was $2.10M, a 3.80% increase from fiscal 2022.
- Aquestive Therapeutics, Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2022 was $2.02M.
- Aquestive Therapeutics, Inc. payment for debt extinguishment or debt prepayment cost for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Payment for Debt Extinguishment or Debt Prepayment Cost 3 month | Payment for Debt Extinguishment or Debt Prepayment Cost 6 month | Payment for Debt Extinguishment or Debt Prepayment Cost 9 month | Payment for Debt Extinguishment or Debt Prepayment Cost 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $0.00 derived: sum of 2 quarters · filed 2025-03-05 | $0.00 derived: sum of 3 quarters · filed 2025-03-05 | $0.00 10-K · filed 2025-03-05 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | $1.07M derived: sum of 4 quarters · filed 2025-03-05 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $0.00 10-Q · filed 2024-08-06 | $1.07M derived: sum of 3 quarters · filed 2025-03-05 | $1.07M derived: sum of 4 quarters · filed 2025-03-05 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $1.07M derived: sum of 2 quarters · filed 2025-03-05 | $1.07M derived: sum of 3 quarters · filed 2025-03-05 | $1.07M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $1.07M derived: sum of 2 quarters · filed 2025-03-05 | $1.07M derived: sum of 3 quarters · filed 2025-03-05 | $2.10M 10-K · filed 2025-03-05 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $1.03M 10-Q · filed 2024-11-04 | $1.70M derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $1.03M 10-Q · filed 2024-08-06 | $1.70M derived: sum of 3 quarters · filed 2024-08-06 | $2.38M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $1.03M 10-Q · filed 2024-05-07 | $1.70M derived: sum of 2 quarters · filed 2024-05-07 | $2.38M derived: sum of 3 quarters · filed 2024-05-07 | $3.05M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $675.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $1.35M derived: sum of 2 quarters · filed 2024-03-05 | $2.02M derived: sum of 3 quarters · filed 2024-03-05 | $2.02M 10-K · filed 2024-03-05 |
| 2022-09-30 | $675.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $1.35M derived: sum of 2 quarters · filed 2023-11-06 | $1.35M 10-Q · filed 2023-11-06 | $1.35M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $675.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $675.00K 10-Q · filed 2023-08-07 | $675.00K derived: sum of 3 quarters · filed 2023-08-07 | $675.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-02 | $0.00 derived: sum of 2 quarters · filed 2023-05-02 | $0.00 derived: sum of 3 quarters · filed 2023-05-02 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $0.00 derived: sum of 2 quarters · filed 2023-03-31 | $0.00 10-K · filed 2023-03-31 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $0.00 10-Q · filed 2022-11-01 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-02 | |||
| 2020-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | $2.25M 10-K · filed 2022-03-08 | ||
| 2020-09-30 | $0.00 10-Q · filed 2020-11-04 | |||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $2.94M derived: sum of 2 quarters · filed 2021-03-09 | $2.94M 10-K · filed 2021-03-09 | |
| 2019-09-30 | $2.94M 10-Q · filed 2020-11-04 | $2.94M 10-Q · filed 2020-11-04 | ||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $0.00 10-K · filed 2020-03-11 | ||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |